Document:

Amendment to Rights Agreement

 Exhibit 4.1 
 AMENDMENT TO RIGHTS AGREEMENT 
 This AMENDMENT, dated as of August 31, 2009 (the
“Amendment”), amends the Rights Agreement, dated as of December 6, 2001 (the “Rights Agreement”), between Soapstone Networks Inc. f/k/a Avici Systems Inc., a Delaware corporation (the “Company”) and Mellon Investor
Services LLC, as Rights Agent (the “Rights Agent”). Capitalized terms not defined herein have the definitions assigned to them in Rights Agreement. 
 WHEREAS, under Section 27 of the Rights Agreement, the Company may from time to time supplement or amend the Rights Agreement without the approval of any holders of Rights Certificates in order to, among
other things, change or adopt any provisions with respect to the Rights that the Company may deem necessary or desirable, any such supplement or amendment to be evidenced by a writing signed by the Company and the Rights Agent; 
 WHEREAS, the Company has determined, and has so directed the Rights Agent, to amend the Rights Agreement as set forth herein pursuant to
Section 27 of the Rights Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth
herein, and intending to be legally bound, the parties hereto agree as follows: 
 1. The definition of “Final Expiration Date”
contained in Section 1 of the Rights Agreement is hereby deleted in its entirety and replaced with the following language: 
 “FINAL
EXPIRATION DATE” shall mean September 14, 2009. 
 2. Exhibits B and C to the Rights Agreement entitled “Form of Right
Certificate” and “Summary of Rights to Purchase Preferred Shares,” respectively, are hereby amended to replace the words “December 5, 2011” with the words “September 14, 2009” in all places where such words appear.

 3. This Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by
and construed in accordance with the laws of the State applicable to contracts to be made and performed entirely within such State; provided, however, that all provisions regarding the rights, duties and obligations of the Rights Agent
shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed entirely within such State. 
 4. By execution of this Amendment, the Company hereby certifies to the Rights Agent that this Amendment is in compliance with the terms of Section 27 of the Rights Agreement. 
 5. All acts and things necessary to make this Amendment a valid agreement, enforceable according to its terms, have been done and performed, and the
execution and delivery of this Amendment by the Company and the Rights Agent have been in all respects duly authorized by the Company and the Rights Agent. 
 6. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and such counterparts shall together constitute but one and the same
instrument. 
 7. In all respects not inconsistent with the terms and provisions of this Amendment, the Rights Agreement is hereby ratified,
adopted approved and confirmed. In executing and delivering this Amendment, the Rights Agent shall be entitled to all the privileges and immunities afforded to the Rights Agent under the terms and conditions of the Rights Agreement. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and attested, as of
the date first set forth above. 
  

			
	SOAPSTONE NETWORKS INC.
		
	By:	 	 /s/ William J. Stuart

	Name:	 	William J. Stuart
	Title:	 	President and CFO
	
	MELLON INVESTOR SERVICES LLC
		
	By:	 	 /s/ Judy Hsu

	Name:	 	Judy Hsu
	Title:	 	Vice President – Relationship ManagerConvertible Subordinated Promissory Note Fourth Extension Agreement

 Exhibit 10.1 
 CONVERTIBLE SUBORDINATED PROMISSORY NOTE MATURITY DATE 
 FOURTH EXTENSION AGREEMENT 
 Whereas, Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), borrowed $508,896 from Life Sciences Opportunities Fund II (Institutional),
L.P. , a Delaware Limited Partnership (the “Lender”), pursuant to that certain Convertible Subordinated Promissory Note, dated as of December 5, 2007(the “Note”); and 
 Whereas, the Maturity Date of the Note was extended from May 15 2009 to July 15, 2009, pursuant to an Extension Agreement dated April 6, 2009, between the
Company and the Lender; the Maturity Date of the Note was further extended from July 15, 2009 to August 15, 2009, pursuant to the Second Extension Agreement dated July 13, 2009, between the Company and the Lender; and the Maturity
Date of the Note was further extended from August 15, 2009 to August 31, 2009, pursuant to the Third Extension Agreement dated August 14, 2009, between the Company and the Lender; 
 Whereas, no principal and interest have been paid to date on the Note; and 
 Whereas, the Company has requested that the Lender extend the Maturity Date of the Note and all principal and interest due thereon to September 15, 2009; 
 For good and valuable consideration, the Company and the Lender agree as follow: 
 The Maturity Date of the Note is hereby
extended to September 15, 2009 and all principal and interest due and payable on the Note shall be due and payable on September 15, 2009 (the “Fourth Extension”). All of the other terms and conditions of the Note, the Convertible
Note Purchase and Warrant Agreement between the Company and the Lender dated as of December 5, 2007, as amended as of December 19, 2007, the Warrant to purchase 67,853 shares of the Company’s Common Stock issued by the Company to the
Lender on December 5, 2007 and the Registration Rights Agreement between the Company and the Lender dated as of December 5, 2007, shall remain in full force and effect and were not and are not amended in any manner by the Extension
Agreement, the Second Extension Agreement, the Third Extension Agreement and this Fourth Extension Agreement. 
 Dated: August 31, 2009 
  

			
	 LIFE SCIENCES OPPORTUNITIES FUND
 II
(INSTITUTIONAL), L.P.

		
	By:	 	 /s/    Al Hansen

		 	Signet Healthcare Partners, LLC, General Partner
		 	Al Hansen, Managing Director

 Bioject Medical Technologies, Inc. 
  

			
	 By:
	 	 /s/    Ralph Makar

		 	Ralph Makar
		 	President and Chief Executive OfficerConvertible Subordinated Promissory Note Second Extension Agreement

 Exhibit 10.2 
 CONVERTIBLE SUBORDINATED PROMISSORY NOTE MATURITY DATE 
 FOURTH EXTENSION AGREEMENT 
 Whereas, Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), borrowed $91,104 from Life Sciences Opportunities Fund II, L.P., a Delaware
Limited Partnership (the “Lender”), pursuant to that certain Convertible Subordinated Promissory Note, dated as of December 5, 2007 (the “Note”); and 
 Whereas, the Maturity Date of the Note was extended from May 15 2009 to July 15, 2009, pursuant to an Extension Agreement dated April 6, 2009, between the Company and the Lender; the Maturity Date of
the Note was further extended from July 15, 2009 to August 15, 2009, pursuant to the Second Extension Agreement dated July 13, 2009, between the Company and the Lender; and the Maturity Date of the Note was further extended from
August 15, 2009 to August 31, 2009, pursuant to the Third Extension Agreement dated August 14, 2009, between the Company and the Lender; 
 Whereas, no principal and interest have been paid to date on the Note; and 
 Whereas, the Company has requested that the Lender extend the Maturity
Date of the Note and all principal and interest due thereon to September 15, 2009; 
 For good and valuable consideration, the Company and the Lender
agree as follow: 
 The Maturity Date of the Note is hereby extended to September 15, 2009 and all principal and interest due and payable on the Note
shall be due and payable on September 15, 2009 (the “Fourth Extension”). All of the other terms and conditions of the Note, the Convertible Note Purchase and Warrant Agreement between the Company and the Lender dated as of
December 5, 2007, as amended as of December 19, 2007, the Warrant to purchase 12,147 shares of the Company’s Common Stock issued by the Company to the Lender on December 5, 2007 and the Registration Rights Agreement between the
Company and the Lender dated as of December 5, 2007, shall remain in full force and effect and were not and are not amended in any manner by the Extension Agreement, the Second Extension Agreement, the Third Extension Agreement and this Fourth
Extension Agreement. 
 Dated: August 31, 2009 
  

			
	LIFE SCIENCES OPPORTUNITIES FUND II, L.P.
		
	By:	 	 /s/    Al Hansen

		 	Signet Healthcare Partners, LLC, General Partner
		 	Al Hansen, Managing Director

 Bioject Medical Technologies, Inc. 
  

			
	By:	 	 /s/    Ralph Makar

		 	Ralph Makar
		 	President and Chief Executive OfficerAmendment to Letter Agreement

 Exhibit 10.4 
 September 1, 2009 
 Mr. Dinesh Paliwal 
 Dear Dinesh: 
 Reference is made to the Letter Agreement, dated as of May 8, 2007, as amended on November 29, 2007 and
December 26, 2008 (the “Letter Agreement”), by and between Harman International Industries, Incorporated (the “Company”) and you. Capitalized terms not defined herein shall have the meanings ascribed to such
terms in the Letter Agreement. 
 The purpose of this letter is to evidence certain additional understandings between you and the Company, as
follows: 
 1. Annual Bonus: Effective with the Company’s fiscal year commencing July 1, 2009 (“Fiscal 2010”), you will be
eligible for an annual cash target bonus opportunity equal to 200% of your Base Salary and a maximum bonus of 300% of your Base Salary (the “Annual Bonus”). The Annual Bonus shall be based upon Harman’s achievement of its
business plan targets as established annually by the Compensation Committee consistent with the Company’s 2008 Key Executive Officers Bonus Plan or its successor (the “Bonus Plan”). All or a portion of the Annual Bonus shall be
awarded pursuant to the terms of the Bonus Plan or other applicable bonus plan, and the Annual Bonus shall be paid no later than March 15th of the calendar year immediately following the end of the applicable fiscal year. Your eligibility for
the Annual Bonus shall be in lieu of, and not in addition to, any other rights that you may have to participate in the Bonus Plan. The provisions of this paragraph supersede the terms of Paragraph 5 of the Letter Agreement. 
 2. Fiscal 2010 Restricted Share Unit Awards: As of the date hereof, you will receive a time-based vesting restricted share unit grant in respect of 81,967 shares
of Company common stock, in the form of grant set forth as Exhibit A hereto, and a performance-based vesting restricted share unit grant in respect of 163,934 shares of Company common stock, in the form of grant set forth as Exhibit B hereto.

 3. Future Equity Grants. Paragraph 6 of the Letter Agreement is hereby deleted in its entirety, it being understood that such deletion shall not
affect the terms of any outstanding awards granted prior to Fiscal 2010. With respect to the Company’s fiscal years commencing July 1, 2010, 2011 and 2012, you will be eligible for annual equity grants on a basis commensurate with your
title and position at the Company (the “Annual Equity Awards”) under the Company’s then in-force equity award plan. The Annual Equity Awards in respect of an amount of Company common shares will have a grant date total
opportunity equal to at least 600% of your Base Salary, with time-based vesting awards having a grant date total value of at least 200% of your Base Salary (a “Future Time-Based Award”) and the opportunity to earn (assuming
achievement of the maximum level of performance) the remaining portion of the total 

 
value of the Annual Equity Awards as a performance-based vesting award (a “Future Performance-Based Award”). The form and provisions of each
Future Time-Based Award shall be established in good-faith by the Compensation Committee, provided that, except as otherwise agreed between you and the Compensation Committee, each Time-Based Award shall (i) have a vesting period of no
more than three years from the applicable grant date and (ii) provide for full accelerated vesting upon a Protected Termination and a change in control. The form and provisions of each Future Performance-Based Award shall be established in
good-faith by the Compensation Committee, provided that, except as otherwise agreed between you and the Compensation Committee, each Future Performance-Based Award shall (i) have a vesting period of no more than three years from the
applicable grant date with all performance metrics and goals to be established by the Compensation Committee and (ii) provide for (A) upon a Protected Termination on or prior to the date that is six months from the date of grant, vesting
of 50% of the number of Future Performance-Based Awards determined to be earned based on the achievement of the applicable performance metrics and goals, (B) upon a Protected Termination following the date that is six months after the date of
grant, full vesting of the number of Future Performance-Based Awards determined to be earned based on the achievement of the applicable performance metrics and goals, and (C) upon a change in control, vesting consistent with the change in
control vesting methodology set forth in Section 4(b) of Exhibit B attached hereto; provided, further, however, that such Future Performance-Based Award on a Protected Termination will be paid or settled only if the
applicable threshold, target and/or maximum performance metrics and goals have been determined to have been met by the Compensation Committee at the end of the applicable performance cycle. To the extent that the required grant amounts exceed any
applicable equity plan limits, you and the Compensation Committee will mutually agree on an alternative compensation award equal to the value of such excess. The grant date value of each Annual Equity Award shall be determined based on the fair
market value of the shares of Company common stock (or that of any successor) (or, in the case of stock options and stock appreciation rights, the value of such stock options or stock appreciation rights) on the date of grant, applying the
methodology employed by the Company for awarding equity compensation awards. Each Annual Equity Award will provide for an automatic reduction in the number of shares otherwise required to be delivered to you, as applicable, to cover minimum required
withholding (and exercise price, if applicable) unless and to the extent such reduction is prohibited by a material financing or other agreement that restricts the ability of the Company to permit such reduction. With respect to the Company’s
fiscal years commencing July 1, 2013 and thereafter, you will be eligible for annual equity incentive awards on a basis commensurate with your title and position at the Company. 
 4. Deletion of Section 7(f). Section 7(f) of the Letter Agreement is hereby deleted in its entirety, and you shall have no further rights under such deleted Section 7(f). 

 This letter is intended to constitute an amendment to the Letter Agreement which, subject to the
provisions hereof, shall otherwise remain in full force and effect. In order to evidence your agreement to the foregoing, please sign and return the enclosed copy of this document, which shall constitute a binding agreement between the Company and
you. 
 Sincerely, 
  

			
	 /s/ John G. Stacey

	Name:	 	John G. Stacey
	Title:	 	Vice President HR and Chief Human Resources Officer
	
	 /s/ Edward H. Meyer

	Name:	 	Edward H. Meyer
	Title:	 	Chairman of the Compensation Committee
	
	ACCEPTED AND AGREED:
	
	 /s/ Dinesh Paliwal

	Dinesh Paliwal
	Date:	 	September 1, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]